Last reviewed · How we verify

chondrocyte-alginate gel suspension

FDA Office of Orphan Products Development · Phase 3 active Small molecule

chondrocyte-alginate gel suspension is a Cell therapy Small molecule drug developed by FDA Office of Orphan Products Development. It is currently in Phase 3 development for Cartilage repair for osteoarthritis.

Chondrocyte-alginate gel suspension is a cell-based therapy that delivers chondrocytes to repair damaged cartilage.

Chondrocyte-alginate gel suspension is a cell-based therapy that delivers chondrocytes to repair damaged cartilage. Used for Cartilage repair for osteoarthritis.

At a glance

Generic namechondrocyte-alginate gel suspension
SponsorFDA Office of Orphan Products Development
Drug classCell therapy
ModalitySmall molecule
Therapeutic areaOrthopedics
PhasePhase 3

Mechanism of action

This treatment involves encapsulating chondrocytes in an alginate gel matrix, which is then injected into the affected joint. The chondrocytes help to repair and regenerate damaged cartilage tissue.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about chondrocyte-alginate gel suspension

What is chondrocyte-alginate gel suspension?

chondrocyte-alginate gel suspension is a Cell therapy drug developed by FDA Office of Orphan Products Development, indicated for Cartilage repair for osteoarthritis.

How does chondrocyte-alginate gel suspension work?

Chondrocyte-alginate gel suspension is a cell-based therapy that delivers chondrocytes to repair damaged cartilage.

What is chondrocyte-alginate gel suspension used for?

chondrocyte-alginate gel suspension is indicated for Cartilage repair for osteoarthritis.

Who makes chondrocyte-alginate gel suspension?

chondrocyte-alginate gel suspension is developed by FDA Office of Orphan Products Development (see full FDA Office of Orphan Products Development pipeline at /company/fda-office-of-orphan-products-development).

What drug class is chondrocyte-alginate gel suspension in?

chondrocyte-alginate gel suspension belongs to the Cell therapy class. See all Cell therapy drugs at /class/cell-therapy.

What development phase is chondrocyte-alginate gel suspension in?

chondrocyte-alginate gel suspension is in Phase 3.

What are the side effects of chondrocyte-alginate gel suspension?

Common side effects of chondrocyte-alginate gel suspension include Joint pain, Swelling.

Related